Woman's Death Blamed on Psoriasis Drug Raptiva
-Courthouse News Service
03/09/2010 - The psoriasis drug Raptiva killed a woman by giving her viral encephalitis, her mother and son claim in Superior Court. Raptiva was pulled from the U.S. market on June 8, 2009 after dangerous side effects and deaths from infections were reported across Europe, Canada and the United States. More>>>
Warnings strengthened for Tysabri
-Pharmacy News
10/29/2009 - A growing association between a widely used multiple sclerosis drug Tysabri (natalizumab) and a potentially deadly brain infection has been reflected in strengthened warnings for prescribers and patients. More>>>
PML Found in Patient on Rituximab Monotherapy
-Medpage Today
10/24/2009 - A case of progressive multifocal leukoencephalopathy (PML) has been reported in a rheumatoid arthritis patient taking rituximab (Rituxan) who had not previously received anti-tumor necrosis factor therapy, according to the FDA and the drug's manufacturer. More>>>
Just in: the psoriasis drug Raptiva has been banned in Europe
-Examiner
06/12/2009 - In a manner similar to the COX inhibitor Vioxx, Raptiva became the latest victim of the pharmaceutical industry world-wide due to the development of serious side-effects in patients. Raptiva was approved in the US in 2003 and in Europe reaping millions of dollars in sales world-wide before being pulled from the market due to the reports of a multitude of side-effects in patients. More>>>
EU-wide Recall of Raptiva (efalizumab) to be Initiated
-PharmaLive
06/08/2009 - LONDON - The European Medicines Agency has agreed to an EU-wide recall of all of the remaining batches of Raptiva, from Merck Serono. This means that within the next few days all batches of Raptiva will be recalled from wholesalers, pharmacies and hospitals. Following this, the medicine will no longer be available anywhere in the European Union. More>>>
Reports of Brain Virus from Common Cancer Drug
-EmaxHealth
05/26/2009 - So far, 57 cases of an often fatal brain virus have been reported in association with administration of the cancer drug rituximab. The reports span 1997 to 2008, and include patients with anemia, rheumatoid arthritis and lymphoma, who developed the brain virus, progressive multifocal leukoencephalitis (PML). More>>>
Psoriasis Drug Raptiva Pulled From U.S. Market
-Forbes
04/27/2009 - The troubled psoriasis drug Raptiva is being withdrawn from the U.S. market, California-based drug maker Genentech ( DNA - news - people ) announced Wednesday. The move comes almost two months after U.S. health officials issued a public health advisory on the drug after confirming a link to a rare, sometimes fatal brain infection. More>>>
Genentech Removing Raptiva From U.S. Market: Announcement Follows Reports of Three Deaths Associated With Use of Psoriasis Drug
-AAFP
04/11/2009 - Drug manufacturer Genentech has announced that it is voluntarily withdrawing its psoriasis drug efalizumab, which is marketed as Raptiva, because of life-threatening infections associated with use of the medication. More>>>
FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market
-FDA
04/08/2009 - Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this action because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. More>>>
And the Drug Companies and FDA Try to Kill Us Again in the name of Profits.
-Motley Fool
03/13/2009 - Leave it to the FDA to wait until the last minute to finally sound the alarm a drug with deadly side effects. By now, I'm sure you've heard that Genetech's psoriasis drug Raptiva not only might cause a brain infection, but it could even kill you. That's a heck of a risk to be taking to clear up your skin. More>>>
Raptiva Side Effects Include Meningitis
-LawyersandSettlements
03/03/2009- Springfield, IL: Kristina says she took only one dose of Raptiva before being rushed to the emergency room 24 hours later. "They suspected meningitis," says Kristina, "then one of the doctors at the hospital did some research and told me there were 2 other reported cases of meningitis associated with Raptiva." More>>>
Raptiva Puts Patients At Risk For PML
-InjuryBoard
03/02/2009- Patients taking the Genentech product, Raptiva, for psoriasis are being warned by the Food and Drug Administration (FDA) about the risk of developing a rare brain infection. A fourth possible report of progressive multifocal leukoencephalopathy (PML) has yet to be confirmed. Three out of the four instances have ended in death, and each patient had been taking the medicine for more than three years. More>>>
Raptiva Recall in Canada and Europe Due to Risk of PML Brain Infection
-AboutLawsuits
02/27/2009- Following recommendations that a Raptiva recall be issued due to a potential risk of users developing a deadly brain infection, sales of the psoriasis drug are being suspended in Canada and Europe. In the United States, the FDA is continuing to review whether the benefits of Raptiva outweigh the risks, and have urged doctors to carefully monitor any patients receiving the treatment. More>>>
Local doctors urge caution with psoriasis drug Raptiva
-Newsday
02/25/2009- Some Long Island doctors are urging caution about a potent psoriasis drug linked to a deadly brain infection, as a report in a major medical journal today encourages more conservative prescribing for all medications. Raptiva, a drug that erases the red and scaly patches of psoriasis by tamping down the immune system, is the subject of a public health alert issued by the U.S. Food and Drug Administration in the wake of three deaths and a possible fourth. More>>>
Psoriasis drug may be linked to fatal infection
- Seattle Times
02/23/2009- The Food and Drug Administration (FDA) warned U.S. patients last week that it is investigating the possibility of a link between the psoriasis drug marketed as Raptiva, or efalizumab, and at least three deaths caused by a rare brain infection called progressive multifocal leukoencephalopathy. The agency is looking into a fourth, unconfirmed, report of the deadly infection in a patient taking Raptiva. More>>>
